Dimethyllysergamide: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==References== |
|||
{{Unreferenced|date=December 2009}} |
|||
{{Reflist}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
| Watchedfields = changed |
Revision as of 19:40, 8 September 2013
References
Clinical data | |
---|---|
Other names | DAM-57, Lysergic acid dimethylamide |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21N3O |
Molar mass | 295.39 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
'N,N-Dimethyllysergamide or "N,N-dimethyl-D-lysergamide"' (DAM-57) is a derivative of ergine. There has been a single report of observing N,N-dimethyl-D-lysergamide in the illicit drug market. [1] It may cause LSD-like effects at doses of 1 milligram or more but this is disputed.
- ^ A. B. Clark, Microgram., 6, 37 (1973)